

3-Bromooxindoles as Nucleophiles in Asymmetric Organocatalytic Mannich Reactions with *N*-Ts-imines

Jianhao Li, Taiping Du, Gang Zhang* and Yungui Peng*

School of Chemistry and Chemical Engineering, Southwest University, Chongqing 400715, P. R. China

Fax: (+86) 02368253157; E-mail: pengyungui@hotmail.com

Department of High Altitude Military Hygiene, College of High Altitude Military Medicine, Third Military Medical University, Chongqing 400038, P. R. China

E-mail: zhanggang1968@yahoo.com.cn

Table of Contents


1. General methods	2
2. Synthesis of chiral catalysts	2
3. Asymmetric Mannich reaction of 3-bromooxindole with <i>N</i> -Ts-imine catalyzed by other catalysts	7
4. Optimization of the reaction conditions.....	9
5. Determination of the absolute configuration of the major diastereomer.....	10
6. General procedure for synthesis of 3-bromo 3, 3'-disubstituted oxindoles via asymmetric <i>anti</i> -Mannich reaction	11
7. Characterization of the <i>anti</i> -Mannich reaction products.....	11
8. Synthesis of aziridine via the product of <i>anti</i> -Mannich reaction.....	17
9. References.....	18
10. NMR spectra and HPLC for catalysts and <i>anti</i> -Mannich reaction products.....	19

1. General methods

All solvents were purified by standard procedures and distilled prior to use. Reagents obtained from commercial source were used without further purification. Petroleum ether and ethyl acetate for flash column chromatography were distilled before use. All reactions were monitored by TLC with silica gel coated plates. Flash column chromatography was performed on silica gel H (10–40 μ). ^1H NMR and ^{13}C NMR spectra were recorded on a Bruker Avance 300 spectrometer, respectively. Chemical shifts are reported in ppm from tetramethyl silane (TMS) with the solvent resonance as the internal standard. Proton signal multiplicities are given as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad) or a combination of them. *J*-values are in Hz. HRMS (Bio TOF Q) spectra were recorded on P-SIMS-Gly of Bruker Daltonics Inc. Optical rotations were measured on a Perkin Elmer 341 Polarimeter at $\lambda = 589$ nm. Analytical high performance liquid chromatography (HPLC) was carried out on WATERS 510 instrument (2487 Dual λ Absorbance Detector and 515 HPLC Pump) using chiral column, Chiralpak columns purchased from Daicel Chemical Industries, LTD.

2. Synthesis of chiral catalysts


The preparation of catalyst precursor's 2- R^4 -QD- NH_2 [1-4]



Trifluoroacetic acid (1.12 mL, 15 mmol, 3.0 equiv.) was added to the solution of **QD** (1.62 g, 5 mmol, 1.0 equiv.) in dichloromethane (25 mL), phenylboronic acid (1.22 g, 10 mmol, 2.0 equiv.) and silver (I) nitrate (170 mg, 0.1 mmol, 0.2 equiv.) in water (10 mL) were added subsequently, then potassium persulfate (2.72 g, 10 mmol, 2.0 equiv.) was added. The resulted solution was stirred vigorously at room temperature for 4 h, additional phenylboronic (0.61 mg, 0.125 mmol, 1.0 equiv.) was added, and the reaction was further stirred for 9 h, diluted with dichloromethane (40 mL) and washed with 2 M NaOH (3×30 mL). The layers were separated, and the aqueous layer was extracted with 70% CHCl_3 , 30% isopropyl alcohol (6×30 mL), and the combined organic layers were concentrated under reduced pressure. Purification was performed by column chromatography to provide **5aa** in 50% yield.

5aa (2.5 mmol) and triphenylphosphane (0.786 g, 3 mmol, 1.2 equiv.) were dissolved in dry THF (10 mL) and the solution was cooled to 0 °C. Diisopropyl azidocarboxylate (0.62 mL, 3 mmol, 1.2 equiv.)


was added in one portion. A solution of diphenyl phosphoryl azide (0.66 mL, 3 mmol 1.2 equiv.) in dry THF (2 mL) was then added drop wise at 0 °C. The mixture was allowed to warm to room temperature. After having been stirred for 12 h, the solution was heated at 50 °C for 2h. Triphenyl phosphane (0.85 g, 3.25 mmol) was then added and heating was maintained until the gas evolution had ceased (2 h). The solution was cooled to room temperature, water (0.3 mL) was added, and the solution was stirred for 3 h. Solvents were removed in vacuo and the residue was dissolved in CH₂Cl₂ (12 mL) and diluted hydrochloric acid (10%, 12 mL). The aqueous phase was washed with CH₂Cl₂ (3×12 mL). The aqueous phase was then alkalinized with an excess of concd. aqueous ammonia and washed with CH₂Cl₂ (3×12 mL). The CH₂Cl₂ solutions were dried with Na₂SO₄ and concentrated. The concentrated organic phase was purified by column chromatography on silica gel with elution with CHCl₃/MeOH/aq. NH₄OH (50/1/0.1) to afford a yellow solid **5ab**. **5ab** was then directly used to the next step.




In a 50 mL Schlenk tube flushed with argon was charged with LiCl (1.26 g, 30 mmol), magnetic stir bar and sealed with septum. Mg (1.08 g, 45 mmol) and 0.5 mL of THF were added under argon. 2 mL of a solution of aryl bromide in THF (30 mmol was dissolved in 15 mL) was added to the slurry and stirred vigorously. The formation of Grignard reagents was initiated in one minute (which was realized by the generation of heat), and then remaining aryl bromide was added slowly by maintaining the same temperature. After the addition of aryl bromide, the reaction mixture was stirred for 15 – 30 min at rt.

Aryl magnesium bromide (30 mmol, 0.25M in THF) was diluted with toluene and evaporated under the vacuum. After removing solvent, 10 mL of toluene was added. **QD-NH₂** (0.969 g, 3 mmol) was added to this solution and the mixture was heat to 80 °C for 15 h. The reaction mixture was quenched with aq. NH₄Cl and water; the organic phase was dried over anhydrous MgSO₄ and evaporated. The crude product was purified by column chromatography (CHCl₃/MeOH/aq. NH₄OH = 50/1/0.1) to provide **5eb** as a yellow solid.

General procedure for the preparation of catalysts




3,5-Bis(trifluoromethyl)phenyl isothiocyanate (1 mmol) in anhydrous DCM (2 mL) was added to a solution of catalyst precursors **QD-NH₂** of **4c** (or **5**) (1 mmol) in anhydrous DCM (5 mL) at 0 °C. TLC analysis indicated completion of the reaction. The reaction mixture was concentrated in vacuo. The residue was purified directly by column chromatography on silica gel (CH₃Cl/MeOH/cc. aq. NH₄OH = 200/1/1 as eluant) and then neutral Al₂O₃ (EA/PE = 3/1 as eluant) affording thiourea as a solid.



1-(3,5-bis(trifluoromethyl)phenyl)-3-((R)-(6-isopropoxyquinolin-4-yl)((1S, 2S, 4S, 5R)-5-vinylquinuclidin-2-yl)methyl)thiourea (4c**)**

Catalyst precursor QD-NH₂ of **4c** was prepared according to literature known procedure.^[1, 5] The pure product **4c** was obtained as a white solid in 94% yield. mp:


131–133 °C, $[\alpha]_D^{25} = +173$ (c = 1, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 8.69 (d, *J* = 4.2 Hz, 1H), 8.04 (d, *J* = 9.2 Hz, 1H), 7.88 (s, 2H), 7.67 (s, 1H), 7.53 (s, 1H), 7.40 (dd, *J* = 9.2, 2.1 Hz, 1H), 7.37 (m, 1H), 5.83–5.78 (m, 2H), 5.17–5.11 (m, 2H), 4.76–4.72 (m, 1H), 3.04–2.93 (m, 4H), 2.38 (dd, *J* = 14.9, 7.8 Hz, 1H), 1.83–1.61 (m, 4H), 1.43 (d, *J* = 5.9 Hz, 6H), 1.22 (d, *J* = 5.5 Hz, 1H), 1.04 (dd, *J* = 17.6, 8.2 Hz, 1H). ¹³C NMR (75 MHz, CDCl₃) δ 181.0, 156.4, 147.1, 146.7, 144.4, 140.2, 139.7, 132.4 (q, *J* = 33.8 Hz), 131.5, 128.1, 123.5, 123.0 (q, *J* = 273.0 Hz), 122.6, 120.1, 118.6, 115.2, 104.0, 70.4, 61.4, 48.6, 47.2, 38.8, 27.2, 25.1, 22.1, 21.8. HRMS [EI-(+H)] calcd for C₃₁H₃₃F₆N₄OS 623.2274, found 623.2266.



1-(3,5-bis(trifluoromethyl)phenyl)-3-((R)-(6-methoxy-2-phenylquinolin-4-yl)((1S, 2S, 4S, 5R)-5-vinylquinuclidin-2-yl)methyl)thiourea (5a**).**

The pure product **5a** was obtained as a yellow solid in 88% yield. mp: 124–126 °C,

$[\alpha]_D^{25} = +98$ (c = 1, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 8.15–8.02 (m, 3H), 7.83 (s, 3H), 7.63 (s, 1H), 7.42 (t, *J* = 8.6 Hz, 4H), 7.26 (s, 1H), 5.87 (s, 2H), 5.22–5.15 (m, 2H), 3.96 (s, 3H), 3.36–2.93 (m, 5H), 2.38 (d, *J* = 6.1 Hz, 1H), 1.65 (d, *J* = 32.6 Hz, 3H), 1.31–1.05 (m, 2H). ¹³C NMR (75 MHz, CDCl₃) δ 180.9, 158.1, 154.8, 145.0, 143.9, 142.1, 140.3, 139.2, 135.9, 132.3 (q, *J* = 33.0 Hz), 132.2, 129.2, 128.8, 127.2, 126.5, 123.4, 123.0 (q, *J* = 271.0 Hz), 122.4, 118.6, 115.6, 101.7, 60.4, 55.7, 48.6, 46.9, 38.6, 27.1, 25.8, 25.0, 21.0. HRMS [EI-(+H)] calcd for C₃₅H₃₃F₆N₄OS 671.2274, found 671.2297.




1-(3,5-bis(trifluoromethyl)phenyl)-3-((R)-(6-methoxy-2-(p-tolyl)quinolin-4-yl)((1S, 2S, 4S, 5R)-5-vinylquinuclidin-2-yl)methyl)thiourea (5b**).**

The pure product **5b** was obtained as a yellow solid in 85% yield. mp:


139–140 °C, $[\alpha]_D^{25} = +82$ (c = 1, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 8.08 (d, *J* =

9.2 Hz, 1H), 7.94 (d, $J = 7.6$ Hz, 2H), 7.85 (s, 2H), 7.77 (s, 1H), 7.62 (s, 1H), 7.39 (dd, $J = 9.2, 1.9$ Hz, 1H), 7.24 (d, $J = 6.4$ Hz, 3H), 5.86 (s, 2H), 5.22–5.15 (m, 2H), 3.96 (s, 3H), 3.29 (d, $J = 60.3$ Hz, 2H), 2.97 (dd, $J = 24.5, 10.4$ Hz, 3H), 2.39 (s, 3H), 1.70–1.58 (m, 3H), 1.26 (s, 2H), 1.08 (t, $J = 11.1$ Hz, 1H). ^{13}C NMR (75 MHz, CDCl_3) δ 180.8, 158.0, 154.8, 145.0, 143.8, 142.0, 140.2, 139.3, 139.1, 136.4, 132.2 (q, $J = 33.5$ Hz), 132.1, 129.5, 127.1, 126.5, 123.4, 123.0 (q, $J = 272.8$ Hz), 122.3, 118.5, 115.7, 101.7, 61.7, 55.7, 48.6, 46.9, 38.5, 27.1, 25.7, 25.0, 24.3, 21.3. HRMS [EI-(+H)] calcd for $\text{C}_{36}\text{H}_{35}\text{F}_6\text{N}_4\text{OS}$ 685.2430, found 685.2455.




1-(3,5-bis(trifluoromethyl)phenyl)-3-((R)-(2-(4-ethylphenyl)-6-methoxyquinolin-4-yl)((1S, 2S, 4S, 5R)-5-vinylquinuclidin-2-yl)methyl)thiourea (5c).

The pure product **5c** was obtained as a yellow solid in 79% yield. mp: 112–114 °C, $[\alpha]_{\text{D}}^{25} = +68$ ($c = 1$, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 8.16–8.03 (m, 1H), 7.96 (t, $J = 10.2$ Hz, 2H), 7.80 (d, $J = 19.3$ Hz, 3H), 7.62 (s, 2H), 7.39 (d, $J = 9.1$ Hz, 1H), 7.26 (d, $J = 8.7$ Hz, 3H), 5.86 (s, 2H), 5.21–5.14 (m, 2H), 3.96 (s, 3H), 3.27 (dd, $J = 48.9, 7.5$ Hz, 2H), 2.96 (dd, $J = 25.0, 11.1$ Hz, 3H), 2.69 (dd, $J = 14.9, 7.4$ Hz, 2H), 2.36 (d, $J = 6.6$ Hz, 1H), 1.68 (s, 1H), 1.57 (s, 1H), 1.33–1.23 (m, 5H), 0.97 (dd, $J = 61.8, 7.8$ Hz, 1H). ^{13}C NMR (75 MHz, CDCl_3) δ 181.6, 158.0, 154.8, 145.7, 145.0, 144.1, 142.0, 140.3, 139.3, 136.7, 132.3 (q, $J = 33.8$ Hz), 132.2, 128.4, 127.3, 127.2, 123.4, 123.0 (q, $J = 273.0$ Hz), 122.3, 118.5, 115.6, 101.7, 61.8, 55.7, 48.6, 45.0, 38.6, 29.7, 28.7, 27.2, 25.8, 25.0, 15.5. HRMS [EI-(+H)] calcd for $\text{C}_{37}\text{H}_{37}\text{F}_6\text{N}_4\text{OS}$ 699.2587, found 699.2583.



1-(3,5-bis(trifluoromethyl)phenyl)-3-((R)-(6-methoxy-2-(4-methoxyphenyl)quinolin-4-yl)((1S, 2S, 4S, 5R)-5-vinylquinuclidin-2-yl)methyl)thiourea (5d).


The pure product **5d** was obtained as a yellow solid in 86% yield. mp: 133–135 °C, $[\alpha]_{\text{D}}^{25} = +73$ ($c = 1$, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 8.05 (d, $J = 9.2$ Hz, 1H), 7.96 (d, $J = 7.0$ Hz, 2H), 7.82 (s, 2H), 7.68 (d, $J = 36.6$ Hz, 3H), 7.37 (d, $J = 9.0$ Hz, 1H), 6.93 (d, $J = 7.7$ Hz, 2H), 5.87 (s, 2H), 5.22–5.15 (m, 2H), 3.95 (s, 3H), 3.83 (s, 3H), 3.28 (d, $J = 46.3$ Hz, 2H), 2.95 (dd, $J = 25.0, 11.5$ Hz, 3H), 2.36 (d, $J = 6.2$ Hz, 1H), 1.63 (d, $J = 35.7$ Hz, 3H), 1.25 (dd, $J = 8.5, 5.7$ Hz, 1H), 1.06 (t, $J = 9.1$ Hz, 1H). ^{13}C NMR (75 MHz, CDCl_3) δ 180.8, 160.7, 157.8, 154.4, 146.9, 144.9, 144.1, 142.2, 140.4, 139.3, 132.2 (q, $J = 34.2$ Hz), 131.7, 128.5, 126.5, 123.5, 123.0 (q, $J = 272.9$ Hz), 122.4, 118.5, 115.6, 114.2, 101.8, 61.6, 55.6, 55.4, 48.6, 46.9, 38.5, 27.1, 25.8, 25.0, 24.5. HRMS [EI-(+H)] calcd for $\text{C}_{36}\text{H}_{35}\text{F}_6\text{N}_4\text{O}_2\text{S}$ 701.2379, found 701.2382.




1-(3,5-bis(trifluoromethyl)phenyl)-3-((R)-(2-(4-fluorophenyl)-6-methoxyquinolin-4-yl)((1S, 2S, 4S, 5R)-5-vinylquinuclidin-2-yl)methyl)thiourea (5e).

The pure product **5e** was obtained as a yellow solid in 83% yield. mp: 106–107 °C, $[\alpha]_{\text{D}}^{25} = +98$ ($c = 1$, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 8.08–8.02 (m, 3H), 7.80–7.46 (m, 5H), 7.40 (d, $J = 8.6$ Hz, 1H), 7.13 (d, $J = 7.1$ Hz, 2H), 5.87 (s, 2H), 5.17 (s, 2H), 3.95 (s, 3H), 3.38–2.78 (m, 4H), 2.38 (d, $J = 5.6$ Hz, 1H), 1.66 (d, $J = 27.2$ Hz, 3H), 1.26 (s, 2H), 1.08 (d,


$J = 8.6$ Hz, 1H). ^{13}C NMR (75 MHz, CDCl_3) δ 181.2, 163.6 (d, $J = 248.9$ Hz), 158.1, 153.6, 144.9, 143.8, 142.1, 140.0, 139.4, 135.3, 132.4 (q, $J = 34.3$ Hz), 129.0, 128.9, 126.6, 123.4, 122.9 (q, $J = 272.9$ Hz), 122.5, 118.7, 115.8, 115.6, 101.6, 61.7, 55.6, 48.5, 46.9, 38.6, 29.7, 27.2, 25.9, 25.0. HRMS [EI-(+H)] calcd for $\text{C}_{35}\text{H}_{32}\text{F}_7\text{N}_4\text{OS}$ 689.2180, found 689.2183.




The pure product **5f** was obtained as a yellow solid in 71% yield. mp: 112–113 °C, $[\alpha]_{\text{D}}^{25} = +68$ (c = 1, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 8.14–8.05 (m, 1H), 7.90 (d, $J = 46.4$ Hz, 3H), 7.65 (t, $J = 24.9$ Hz, 3H), 7.33 (dt, $J = 27.9, 13.7$ Hz, 4H), 5.84–5.86 (m, 2H), 5.23–5.16 (m, 2H), 3.94 (d, $J = 15.7$ Hz, 3H), 3.14–2.96 (m, 4H), 2.33 (dd, $J = 40.7, 5.0$ Hz, 1H), 1.26 (s, 3H), 1.06 (s, 2H), 0.87 (d, $J = 7.0$ Hz, 1H). ^{13}C NMR (75 MHz, CDCl_3) δ 181.4, 158.2, 157.8, 153.2, 144.9, 143.8, 142.1, 140.0, 139.2, 137.5, 135.3, 132.4 (q, $J = 33.9$ Hz), 128.9, 128.4, 126.6, 123.3, 123.0 (q, $J = 550.0, 277.1$ Hz), 118.6, 116.9, 115.6, 101.6, 61.8, 55.6, 48.6, 46.9, 38.5, 29.7, 27.1, 25.8, 25.0. HRMS [EI-(+H)] calcd for $\text{C}_{35}\text{H}_{32}\text{ClF}_6\text{N}_4\text{OS}$ 705.1884, found 705.1897.



The pure product **5g** was obtained as a yellow solid in 90% yield. mp: 111–113 °C, $[\alpha]_{\text{D}}^{25} = +100$ (c = 1, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 8.02 (d, $J = 9.1$ Hz, 1H), 7.76 (s, 2H), 7.62 (s, 2H), 7.39 (d, $J = 9.1$ Hz, 1H), 7.10 (s, 6H), 5.80 (s, 2H), 5.11 (d, $J = 5.0$ Hz, 2H), 4.20 (s, 2H), 3.95 (s, 3H), 2.96 (dd, $J = 36.9, 26.9$ Hz, 5H), 2.32 (d, $J = 6.8$ Hz, 1H), 1.60 (d, $J = 24.7$ Hz, 3H), 1.26–1.16 (m, 1H), 0.95–0.88 (m, 1H). ^{13}C NMR (75 MHz, CDCl_3) δ 181.0, 158.3, 157.9, 151.7, 144.5, 144.0, 141.9, 140.1, 139.2, 132.2 (q, $J = 32.7$ Hz), 131.4, 129.0, 128.9, 128.6, 126.4, 123.4, 123.0 (q, $J = 270.2$ Hz), 122.1, 118.4, 115.5, 102.0, 61.5, 55.7, 48.4, 46.9, 44.8, 38.6, 27.2, 25.8, 24.9, 24.3. HRMS [EI-(+H)] calcd for $\text{C}_{36}\text{H}_{35}\text{F}_6\text{N}_4\text{OS}$ 685.2430, found 685.2439.




The pure product **5h** was obtained as a yellow solid in 91% yield. mp: 104–105 °C, $[\alpha]_{\text{D}}^{25} = +104$ (c = 1, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 8.09–8.02 (m, 3H), 7.74 (s, 1H), 7.47 (d, $J = 8.4$ Hz, 1H), 7.34 (d, $J = 17.6$ Hz, 2H), 5.96 (s, 2H), 5.33–5.27 (m, 2H), 4.06 (s, 3H), 3.17–2.96 (m, 7H), 2.52 (d, $J = 5.9$ Hz, 1H), 1.82 (d, $J = 8.8$ Hz, 5H), 1.53–1.37 (m, 3H), 1.21–1.14 (m, 1H), 1.03 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (75 MHz, CDCl_3) δ 180.6, 160.2, 157.7, 144.6, 140.5, 138.8, 132.2 (q, $J = 33.7$ Hz), 131.3, 129.1, 126.1, 126.0, 123.2, 123.0 (q, $J = 272.9$ Hz), 121.9, 118.4, 115.8, 101.9, 61.7, 55.6, 48.5, 46.8, 38.6, 38.4, 32.1, 27.1, 25.6, 24.9, 24.1, 22.7, 13.9. HRMS [EI-(+H)] calcd for $\text{C}_{33}\text{H}_{37}\text{F}_6\text{N}_4\text{OS}$ 651.2587, found 651.2591.













((1*S*, 2*S*, 4*S*, 5*R*)-5-vinylquinuclidin-2-yl)methylthiourea (5i**).^[4]**

The pure product **5i** was obtained as a yellow solid in 88% yield. mp: 115–116 °C, $[\alpha]_D^{25} = +84$ ($c = 1$, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 8.02–7.90 (m, 3H), 7.63 (s, 1H), 7.39 (d, $J = 21.2$ Hz, 3H), 5.78 (s, 2H), 5.10 (d, $J = 8.8$ Hz, 2H), 3.92 (s, 3H), 3.42–2.97 (m, 5H), 2.36 (s, 1H), 1.68 (s, 3H), 1.43 (s, 9H), 1.26 (t, $J = 7.0$ Hz, 1H), 1.06 (d, $J = 6.0$ Hz, 1H). ¹³C NMR (75 MHz, CDCl₃) δ 181.8, 171.2, 166.5, 157.8, 157.2, 144.2, 140.8, 140.0, 135.2, 132.1 (q, $J = 49.7$ Hz), 125.7, 123.4, 123.1 (q, $J = 272.7$ Hz), 121.5, 118.3, 115.5, 101.6, 61.8, 60.4, 55.7, 48.5, 38.6, 37.9, 30.2, 27.2, 25.8, 21.0, 14.2. HRMS [EI-(+H)] calcd for C₃₃H₃₇F₆N₄OS 651.2587, found 651.2584.

3. Asymmetric Mannich reaction of 3-bromooxindole with *N*-Ts-imine catalyzed by other catalysts.^[a]




Entry	Cat.	Yield(%) ^[b]	Dr ^[c]	Ee(%) ^[c]
1		Trace	-	-
2		NR	-	-
3		NR	-	-
4		21	89: 11	43

5		55	89: 11	56
6		49	88: 12	51
7		42	91: 9	-44
8		59	78: 22	-48
9		25	84: 16	-58
10		23	92: 8	-10
11		66	74: 26	-27
12		70	70: 30	0/66
13		55	99:1	-80
14		25	99:1	-83

[a] Reaction conditions: **6a** (0.1 mmol), **7a** (0.12 mmol), **cat.** (0.01mmol), $c = 0.20$ M, -40 °C, 72 h. [b] Yield of the isolated product after purification by column chromatography on silica gel. [c] Determined by HPLC analysis on a chiral stationary phase.


4. Optimization of the reaction conditions ^[a]




Entry	Solvent	x (mol%)	T/°C	c/mol/L	t (h)	Yield (%) ^[b]	Dr ^[c]	Ee (%) ^[c]
1	DCM	10	-40	0.20	72	76	96:4	94
2	CHCl ₃	10	-40	0.20	72	68	96:4	92
3	C ₂ H ₅ Br	10	-40	0.20	72	70	98:2	89
4	(CHCl ₂) ₂	10	-40	0.20	72	45	94:6	90
5	toluene	10	-40	0.20	72	55	96:4	70
6	EA	10	-40	0.20	72	83	95:5	65
7	hexane	10	-40	0.20	72	Trace	-	-
8	Et ₂ O	10	-40	0.20	72	Trace	-	-
9	THF	10	-40	0.20	72	NR	-	-
10	CH ₃ CN	10	-40	0.20	72	NR	-	-
11	DMF	10	-40	0.20	72	NR	-	-
11	ⁱ PrOH	10	-40	0.20	72	NR	-	-
12	DCM	5	-40	0.20	72	51	96:4	94
13	DCM	15	-40	0.20	72	76	96:4	94
14	DCM	10	-40	0.20	24	53	96:4	94
15	DCM	10	-40	0.20	48	66	96:4	94
16	DCM	10	-40	0.20	96	76	96:4	94
17	DCM	10	-40	0.20	120	74	96:4	94
18	DCM	10	-30	0.20	72	68	94:6	94
19	DCM	10	-50	0.20	72	66	97:3	94
20	DCM	10	-40	0.15	72	69	95:5	92
21	DCM	10	-40	0.25	72	70	96:4	94
22 ^[d]	DCM	10	-40	0.20	72	62	96:4	94
23 ^[e]	DCM	10	-40	0.20	72	87	96:4	94
24 ^[f]	DCM	10	-40	0.20	72	91	96:4	94
25 ^[g]	DCM	10	-40	0.20	72	89	96:4	94

[a] Reaction conditions: **6a** (0.1 mmol), **7a** (0.12 mmol). [b] Yield of the isolated product after purification by column chromatography on silica gel. [c] Determined by HPLC analysis on a chiral stationary phase. [d] 4 Å molecular sieves (50 mg) were added. [e] **7a** (0.14 mmol). [f] **7a** (0.15 mmol). [g] **7a** (0.16 mmol).

5. Determination of the absolute configuration of the major diastereomer:




Empirical formula	C ₄₈ H ₄₂ Br ₄ N ₄ O ₁₀ S ₂
Formula weight	1218.62
Temperature	298(2) K
Wavelength	0.71073 Å
Crystal system, space group	Monoclinic, <i>P</i> 2 ₁
<i>a</i> , Å	10.6545(13)
<i>b</i> , Å	20.649(3)
<i>c</i> , Å	13.3304(16)
α , °	90
β , °	99.311(2)
γ , °	90
<i>V</i> , Å ³	2894.1(6)
<i>Z</i> , Calculated density	2, 1.398 Mg/m ³
μ (mm ⁻¹)	2.906
<i>F</i> (000)	1220
GOF	1.081
<i>R</i> ₁ ^a [<i>I</i> > 2σ(<i>I</i>)]	0.0823
<i>wR</i> ₂ ^b [<i>I</i> > 2σ(<i>I</i>)]	0.2286
<i>R</i> ₁ (all data)	0.1212
<i>wR</i> ₂ (all data)	0.2875
Flack parameter	0.022(17)
^a <i>R</i> ₁ = Σ <i>F</i> ₀ - <i>F</i> _c / Σ <i>F</i> ₀ ; ^b <i>wR</i> ₂ = [Σ <i>w</i> (<i>F</i> ₀ ² - <i>F</i> _c ²) ² / Σ <i>w</i> (<i>F</i> ₀ ²)] ^{1/2}	



Proposed transition state model.


To account for the stereochemical outcome, a transition state model was proposed. The two reactive partners were activated concurrently by the catalyst and the nucleophilic attack from both the *Re*-faces of the enolate anion and the *N*-Ts-imine afford the observed products. Other product configurations were deduced based on analogy.

6. General procedure for synthesis of 3-bromo 3', 3'-disubstituted oxindoles via asymmetric *anti*-Mannich reaction




3-bromooxindole **6a** (0.1 mmol, 1 equiv.) was dissolved in anhydrous DCM (0.5 mL), subsequently catalyst **5e** (0.01 mmol, 0.1 equiv.) and *N*-Ts-imine **7a** (0.15 mmol, 1.5 equiv.) were added at -40 °C. After being stirred 72 h, the reaction mixture was purified directly by flash chromatography on silica gel (AcOEt/PE = 1:3) to give the corresponding product.

7. Characterization of the *anti*-Mannich reaction products




N-((*S*)-((*R*)-3-bromo-2-oxoindolin-3-yl)(phenyl)methyl)-4-methylbenzenesulfonamide (**8a**)

The title compound was isolated as yellow solid in 91% yield, mp: 109–111 °C, $[\alpha]_D^{25} = +122$ ($c = 1$, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 8.18 (s, 1H), 7.75 (d, $J = 7.4$ Hz, 1H), 7.49 (d, $J = 8.2$ Hz, 2H), 7.24–7.17 (m, 2H), 7.02 (dd, $J = 13.3, 7.7$ Hz, 3H), 6.87 (t, $J = 7.6$ Hz, 2H), 6.76–6.68 (m, 4H), 4.88 (d, $J = 7.6$ Hz, 1H), 2.28 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 174.2, 143.4, 139.6, 136.2, 133.6, 130.8, 129.3, 128.7, 128.3, 127.7, 127.4, 127.2, 127.0, 123.8, 110.5, 63.8, 58.7, 21.4. HRMS [EI-(+Na)] calcd for C₂₂H₁₉BrN₂NaO₃S 493.0192, found 493.0203. The *ee* and *dr* were determined by a chiral phase Chiralpak IC column (70/30 hexane/*i*PrOH, flow rate 0.5 mL/min, $\lambda = 254$ nm, $t_{\text{major}} = 32.9$ min, $t_{\text{minor}} = 38.5$ min).



N-((*S*)-((*R*)-3-bromo-2-oxoindolin-3-yl)(2-fluorophenyl)methyl)-4-methylbenzenesulfonamide (**8b**)


The title compound was isolated as yellow solid in 94% yield. mp: 92–94 °C, $[\alpha]_D^{25} = +76$ ($c = 1$, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 8.70 (s, 1H), 7.48 (q, $J = 7.9$ Hz, 4H), 7.30–7.28 (m, 1H), 7.16–7.08 (m, 3H), 6.95 (dd, $J = 14.6, 7.9$ Hz, 3H), 6.80 (d, $J = 7.8$ Hz, 1H), 6.72–6.66 (m, 1H), 5.38 (d, $J = 9.0$ Hz, 1H), 2.24 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 175.0, 159.9 (d, $J = 247.9$ Hz), 143.5, 139.6, 135.8, 130.8, 130.2, 130.1, 129.3, 128.4, 127.1, 126.1, 124.0, 123.9, 123.8, 114.8 (d, $J = 22.8$ Hz), 110.8, 57.3, 55.4, 21.4. HRMS [EI-(+Na)] calcd for C₂₂H₁₈BrFN₂NaO₃S 511.0098, found 511.0105. The *ee* and *dr* were determined by a chiral phase Chiralpak AD-H column (76/24 hexane/*i*PrOH, flow rate 0.5 mL/min, $\lambda = 220$ nm, $t_{\text{major}} = 35.8$ min, $t_{\text{minor}} = 28.1$ min).



N-((*S*)-((*R*)-3-bromo-2-oxoindolin-3-yl)(3-fluorophenyl)methyl)-4-methylbenzenesulfonamide (**8c**)


The title compound was isolated as yellow solid in 99% yield, mp: 160–162 °C, $[\alpha]_D^{25} =$

+92 (c = 1, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 8.36 (s, 1H), 7.68 (d, *J* = 7.3 Hz, 1H), 7.51 (d, *J* = 8.2 Hz, 2H), 7.29 (d, *J* = 7.1 Hz, 1H), 7.20 (d, *J* = 7.6 Hz, 1H), 7.04 (d, *J* = 8.2 Hz, 2H), 6.91–6.86 (m, 1H), 6.76 (dd, *J* = 16.6, 7.7 Hz, 3H), 6.63 (d, *J* = 7.8 Hz, 1H), 6.50 (d, *J* = 9.4 Hz, 1H), 4.87 (d, *J* = 7.5 Hz, 1H), 2.30 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 174.2, 161.7 (d, *J* = 246.8 Hz), 143.8, 139.5, 136.3, 136.2, 136.0, 131.0, 129.4, 127.4, 127.1, 126.8, 124.4, 123.9, 116.0 (d, *J* = 23.1 Hz), 115.4 (d, *J* = 20.8 Hz), 110.7, 63.2, 58.1, 21.4. HRMS [EI(+Na)] calcd for C₂₂H₁₈BrFN₂NaO₃S 511.0098, found 511.0111. The *ee* and *dr* were determined by a chiral phase Chiralpak IC column (60/40 hexane/*i*PrOH, flow rate 0.5 mL/min, λ = 254 nm, *t*_{major} = 15.6 min, *t*_{minor} = 29.7 min).




***N*-((*S*)-((*R*)-3-bromo-2-oxoindolin-3-yl)(4-fluorophenyl)methyl)-4-methylbenzenesulfonamide (8d)**

The title compound was isolated as yellow solid in 96% yield, mp: 169–171 °C, [α]_D²⁵ = +109 (c = 1, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 8.36 (s, 1H), 7.76 (d, *J* = 7.0 Hz, 1H), 7.47 (d, *J* = 8.2 Hz, 2H), 7.27 (d, *J* = 7.6 Hz, 1H), 7.19 (t, *J* = 7.3 Hz, 1H), 7.01 (d, *J* = 8.1 Hz, 2H), 6.80 (d, *J* = 7.6 Hz, 1H), 6.73–6.68 (m, 3H), 6.54 (t, *J* = 8.6 Hz, 2H), 4.85 (d, *J* = 7.6 Hz, 1H), 2.28 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 174.2, 162.4 (d, *J* = 248.5 Hz), 143.7, 139.6, 136.2, 131.0, 130.6, 130.5, 129.4, 127.4, 127.0, 126.95, 123.9, 114.7 (d, *J* = 21.6 Hz), 110.7, 63.1, 58.5 (d, *J* = 1.2 Hz), 21.4. HRMS [EI(+Na)] calcd for C₂₂H₁₈BrFN₂NaO₃S 511.0098, found 511.0108. The *ee* and *dr* were determined by a chiral phase Chiralpak AD-H column (76/24 hexane/*i*PrOH, flow rate 0.5 mL/min, λ = 220 nm, *t*_{major} = 21.0 min, *t*_{minor} = 26.4 min).



***N*-((*S*)-((*R*)-3-bromo-2-oxoindolin-3-yl)(2-chlorophenyl)methyl)-4-methylbenzenesulfonamide (8e)**


The title compound was isolated as yellow solid in 84% yield, mp: 174–176 °C, [α]_D²⁵ = +104 (c = 1, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 9.09 (s, 1H), 8.06 (d, *J* = 7.8 Hz, 1H), 7.60 (d, *J* = 8.8 Hz, 1H), 7.51 (d, *J* = 8.2 Hz, 2H), 7.36 (d, *J* = 7.6 Hz, 1H), 7.30 (d, *J* = 7.7 Hz, 1H), 7.23–7.22 (m, 1H), 7.15 (t, *J* = 5.4 Hz, 3H), 6.98 (d, *J* = 8.2 Hz, 2H), 6.88 (d, *J* = 7.6 Hz, 1H), 5.77 (d, *J* = 8.9 Hz, 1H), 2.25 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 175.7, 143.4, 139.6, 135.6, 135.1, 134.4, 130.7, 130.4, 129.4, 129.4, 129.2, 128.7, 127.2, 126.8, 125.7, 123.8, 111.0, 57.5, 56.9, 21.4. HRMS [EI(+Na)] calcd for C₂₂H₁₈BrClN₂NaO₃S 526.9802, found 526.9809. The *ee* and *dr* were determined by a chiral phase Chiralpak IC column (70/30 hexane/*i*PrOH, flow rate 0.5 mL/min, λ = 254 nm, *t*_{major} = 56.1 min, *t*_{minor} = 43.5 min).



***N*-((*S*)-((*R*)-3-bromo-2-oxoindolin-3-yl)(3-chlorophenyl)methyl)-4-methylbenzenesulfonamide (8f)**


The title compound was isolated as yellow solid in 99% yield, mp: 192–193 °C, [α]_D²⁵ = +116 (c = 1, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 8.39 (s, 1H), 7.67 (d, *J* = 7.5 Hz, 1H), 7.47 (d, *J* = 8.2 Hz, 2H), 7.30 (d, *J* = 7.9 Hz, 1H), 7.20 (t, *J* = 7.6 Hz, 1H), 7.02 (t, *J* = 7.7 Hz, 3H), 6.87 (t, *J* = 7.8 Hz, 1H), 6.77–6.66 (m, 4H), 4.82 (d, *J* = 7.4 Hz, 1H), 2.30 (s, 3H). ¹³C NMR (75 MHz, CDCl₃)

δ 174.2, 143.9, 139.5, 135.9, 135.6, 133.5, 131.1, 129.8, 129.4, 129.1, 128.5, 127.3, 127.0, 126.9, 126.6, 123.9, 110.8, 63.2, 58.0, 21.5. HRMS [EI-(+Na)] calcd for $C_{22}H_{18}BrClN_2NaO_3S$ 526.9802, found 526.9806. The *ee* and *dr* were determined by a chiral phase Chiralpak IC column (60/40 hexane/*i*PrOH, flow rate 0.5 mL/min, λ = 254 nm, t_{major} = 15.5 min, t_{minor} = 28.1 min).




***N*-((*S*)-((*R*)-3-bromo-2-oxoindolin-3-yl)(4-chlorophenyl)methyl)-4-methylbenzenesulfonamide (8g)**

The title compound was isolated as yellow solid in 94% yield, mp: 117–119 °C, $[\alpha]_D^{25}$ = +145 (*c* = 1, $CHCl_3$); 1H NMR (300 MHz, $CDCl_3$) δ 8.34 (s, 1H), 7.76 (d, *J* = 7.4 Hz, 1H), 7.48 (d, *J* = 8.2 Hz, 2H), 7.29 (dd, *J* = 7.8, 0.8 Hz, 1H), 7.20 (t, *J* = 7.2 Hz, 1H), 7.03 (d, *J* = 8.1 Hz, 2H), 6.84 (t, *J* = 9.2 Hz, 3H), 6.71 (t, *J* = 8.8 Hz, 3H), 4.85 (d, *J* = 7.6 Hz, 1H), 2.31 (s, 3H). ^{13}C NMR (75 MHz, $CDCl_3$) δ 174.1, 143.9, 139.5, 136.0, 134.4, 132.1, 131.0, 130.1, 129.4, 127.9, 127.4, 127.0, 126.9, 126.4, 124.0, 110.8, 63.2, 58.3, 21.5. HRMS [EI-(+Na)] calcd for $C_{22}H_{18}BrClN_2NaO_3S$ 526.9802, found 526.9811. The *ee* and *dr* were determined by a chiral phase Chiralpak IC column (60/40 hexane/*i*PrOH, flow rate 0.5 mL/min, λ = 254 nm, t_{major} = 18.3 min, t_{minor} = 30.1 min).



***N*-((*S*)-((*R*)-3-bromo-2-oxoindolin-3-yl)(*o*-tolyl)methyl)-4-methylbenzenesulfonamide (8h)**


The title compound was isolated as yellow solid in 89% yield, mp: 166–168 °C, $[\alpha]_D^{25}$ = +100 (*c* = 1, $CHCl_3$); 1H NMR (300 MHz, $CDCl_3$) δ 8.41 (s, 1H), 7.43 (d, *J* = 8.2 Hz, 2H), 7.29 (d, *J* = 8.2 Hz, 2H), 7.10 (t, *J* = 7.6 Hz, 1H), 6.99 (t, *J* = 6.5 Hz, 3H), 6.86 (dd, *J* = 12.4, 7.7 Hz, 2H), 6.78 (dd, *J* = 6.9, 4.3 Hz, 2H), 6.64 (d, *J* = 7.1 Hz, 1H), 5.22 (d, *J* = 7.2 Hz, 1H), 2.28 (s, 3H), 2.05 (s, 3H). ^{13}C NMR (75 MHz, $CDCl_3$) δ 174.5, 143.2, 139.7, 137.2, 136.7, 133.1, 130.8, 130.0, 129.1, 128.4, 127.5, 127.1, 126.8, 126.4, 125.7, 123.7, 110.7, 58.7, 57.6, 21.5, 19.9. HRMS [EI-(+Na)] calcd for $C_{23}H_{21}BrN_2NaO_3S$ 507.0348, found 507.0348. The *ee* and *dr* were determined by a chiral phase Chiralpak IC column (60/40 hexane/*i*PrOH, flow rate 0.5 mL/min, λ = 254 nm, t_{major} = 22.7 min, t_{minor} = 26.0 min).



***N*-((*S*)-((*R*)-3-bromo-2-oxoindolin-3-yl)(*m*-tolyl)methyl)-4-methylbenzenesulfonamide (8i)**


The title compound was isolated as yellow solid in 99% yield, mp: 187–188 °C, $[\alpha]_D^{25}$ = +104 (*c* = 1, $CHCl_3$); 1H NMR (300 MHz, $CDCl_3$) δ 8.15 (s, 1H), 7.74–7.70 (m, 1H), 7.47 (d, *J* = 8.2 Hz, 2H), 7.24–7.16 (m, 2H), 6.99 (d, *J* = 8.1 Hz, 2H), 6.78 (dt, *J* = 15.2, 7.5 Hz, 2H), 6.69 (d, *J* = 7.4 Hz, 1H), 6.54 (dd, *J* = 18.4, 7.4 Hz, 2H), 6.44 (s, 1H), 4.82 (d, *J* = 7.6 Hz, 1H), 2.28 (s, 3H), 1.94 (s, 3H). ^{13}C NMR (75 MHz, $CDCl_3$) δ 174.2, 143.3, 139.6, 137.2, 136.4, 133.4, 130.8, 130.0, 129.7, 129.1, 129.0, 127.7, 127.4, 127.0, 125.4, 123.7, 110.5, 63.8, 58.6, 21.4, 21.0. HRMS [EI-(+Na)] calcd for $C_{23}H_{21}BrN_2NaO_3S$ 507.0348, found 507.0342. The *ee* and *dr* were determined by a chiral phase Chiralpak IC column (60/40 hexane/*i*PrOH, flow rate 0.5 mL/min, λ = 254

nm, $t_{\text{major}} = 20.4$ min, $t_{\text{minor}} = 40.4$ min).




***N*-((*S*)-((*R*)-3-bromo-2-oxoindolin-3-yl)(*p*-tolyl)methyl)-4-methylbenzenesulfonamide (8j)**

The title compound was isolated as yellow solid in 87% yield, mp: 106–107 °C, $[\alpha]_{\text{D}}^{25} = +92$ ($c = 1$, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 8.00 (s, 1H), 7.68 (d, $J = 7.4$ Hz, 1H), 7.49 (d, $J = 8.2$ Hz, 2H), 7.28–7.24 (m, 1H), 7.17 (t, $J = 7.3$ Hz, 1H), 7.02 (d, $J = 8.1$ Hz, 2H), 6.72–6.63 (m, 5H), 6.50 (d, $J = 7.1$ Hz, 1H), 4.82 (d, $J = 7.1$ Hz, 1H), 2.30 (s, 3H), 2.15 (s, 3H). ^{13}C NMR (75 MHz, CDCl_3) δ 174.0, 143.4, 139.6, 138.2, 136.2, 130.8, 130.5, 129.2, 128.7, 128.6, 128.4, 127.5, 127.0, 123.7, 110.5, 63.5, 58.6, 21.4, 21.1. HRMS [EI-(+Na)] calcd for $\text{C}_{23}\text{H}_{21}\text{BrN}_2\text{NaO}_3\text{S}$ 507.0348, found 507.0349. The *ee* and *dr* were determined by a chiral phase Chiralpak IC column (60/40 hexane/*i*PrOH, flow rate 0.5 mL/min, $\lambda = 254$ nm, $t_{\text{major}} = 25.4$ min, $t_{\text{minor}} = 40.8$ min).




***N*-((*S*)-((*R*)-3-bromo-2-oxoindolin-3-yl)(2-methoxyphenyl)methyl)-4-methylbenzenesulfonamide (8k)**

The title compound was isolated as yellow solid in 90% yield, mp: 162–164 °C, $[\alpha]_{\text{D}}^{25} = +68$ ($c = 1$, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 7.99 (s, 1H), 7.49 (d, $J = 8.2$ Hz, 3H), 7.21 (t, $J = 7.6$ Hz, 1H), 7.12–7.02 (m, 3H), 6.96 (d, $J = 8.1$ Hz, 2H), 6.79–6.62 (m, 3H), 6.41 (d, $J = 7.9$ Hz, 1H), 5.26 (s, 1H), 3.28 (s, 3H), 2.24 (s, 3H). ^{13}C NMR (75 MHz, CDCl_3) δ 174.4, 156.5, 143.0, 139.4, 136.8, 131.5, 130.1, 129.6, 129.0, 128.9, 127.2, 123.7, 122.9, 120.4, 111.5, 110.4, 110.1, 58.8, 54.8, 21.4. HRMS [EI-(+Na)] calcd for $\text{C}_{23}\text{H}_{21}\text{BrN}_2\text{NaO}_4\text{S}$ 523.0298, found 523.0292. The *ee* and *dr* were determined by a chiral phase Chiralpak IC column (60/40 hexane/*i*PrOH, flow rate 0.5 mL/min, $\lambda = 254$ nm, $t_{\text{major}} = 49.9$ min, $t_{\text{minor}} = 37.4$ min).



***N*-((*S*)-((*R*)-3-bromo-2-oxoindolin-3-yl)(3-methoxyphenyl)methyl)-4-methylbenzenesulfonamide (8l)**


The title compound was isolated as yellow solid in 99% yield, mp: 106–107 °C, $[\alpha]_{\text{D}}^{25} = +87$ ($c = 1$, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 8.19 (s, 1H), 8.02–7.99 (m, 1H), 7.48 (d, $J = 8.2$ Hz, 2H), 7.31–7.28 (m, 2H), 6.97 (d, $J = 8.2$ Hz, 2H), 6.87 (d, $J = 8.4$ Hz, 1H), 6.71 (dd, $J = 13.0, 5.5$ Hz, 2H), 6.52 (dd, $J = 8.0, 1.8$ Hz, 1H), 6.25 (d, $J = 7.6$ Hz, 1H), 6.11 (s, 1H), 4.87 (d, $J = 8.3$ Hz, 1H), 3.33 (s, 3H), 2.26 (s, 3H). ^{13}C NMR (75 MHz, CDCl_3) δ 174.1, 158.6, 143.5, 139.7, 136.2, 134.7, 130.8, 129.2, 128.6, 127.37, 127.35, 127.2, 124.0, 121.2, 115.4, 112.0, 110.5, 63.9, 58.6, 54.8, 21.4. HRMS [EI-(+Na)] calcd for $\text{C}_{23}\text{H}_{21}\text{BrN}_2\text{NaO}_4\text{S}$ 523.0298, found 523.0315. The *ee* and *dr* were determined by a chiral phase Chiralpak IC column (60/40 hexane/*i*PrOH, flow rate 0.5 mL/min, $\lambda = 254$ nm, $t_{\text{major}} = 19.9$ min, $t_{\text{minor}} = 49.5$ min).



***N*-((*S*)-((*R*)-3-bromo-2-oxoindolin-3-yl)(4-methoxyphenyl)methyl)-4-methylbenzenesulfonamide (8m)**


The title compound was isolated as yellow solid in 88% yield, mp: 107–109 °C, $[\alpha]_{\text{D}}^{25} = +86$ ($c = 1$, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 7.80 (s, 1H), 7.62 (d, J

= 7.4 Hz, 1H), 7.48 (d, J = 8.2 Hz, 2H), 7.29 (d, J = 12.0 Hz, 1H), 7.14 (t, J = 7.5 Hz, 1H), 7.04 (d, J = 8.1 Hz, 2H), 6.68 (t, J = 10.3 Hz, 3H), 6.38 (dd, J = 20.0, 7.6 Hz, 3H), 4.77 (d, J = 6.5 Hz, 1H), 3.63 (s, 3H), 2.29 (s, 3H). ^{13}C NMR (75 MHz, CDCl_3) δ 173.8, 159.5, 143.4, 139.5, 136.2, 130.8, 130.1, 129.3, 127.5, 127.3, 127.0, 125.4, 123.7, 113.1, 110.5, 63.2, 58.6, 55.1, 21.5. HRMS [EI-(+Na)] calcd for $\text{C}_{23}\text{H}_{21}\text{BrN}_2\text{NaO}_4\text{S}$ 523.0298, found 523.0307. The *ee* and *dr* were determined by a chiral phase Chiralpak AD-H column (76/24 hexane/*i*PrOH, flow rate 0.5 mL/min, λ = 220 nm, t_{major} = 25.1 min, t_{minor} = 28.5 min).




***N*-((*S*)-((*R*)-3-bromo-2-oxoindolin-3-yl)(furan-2-yl)methyl)-4-methylbenzenesulfonamide (8o)**

The title compound was isolated as yellow solid in 99% yield, mp: 79–82 °C, $[\alpha]_{\text{D}}^{25}$ = +51 (c = 1, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 8.68 (s, 1H), 7.61–7.49 (m, 3H), 7.24–7.20 (m, 1H), 7.14–7.11 (m, 3H), 6.97 (d, J = 8.4 Hz, 1H), 6.81 (d, J = 7.7 Hz, 1H), 6.52 (d, J = 9.0 Hz, 1H), 6.03 (s, 2H), 5.09 (d, J = 9.0 Hz, 1H), 2.33 (s, 3H). ^{13}C NMR (75 MHz, CDCl_3) δ 174.5, 147.7, 143.5, 142.2, 139.6, 136.4, 130.8, 129.4, 127.9, 127.2, 126.1, 123.7, 110.8, 110.5, 110.2, 57.4, 56.9, 21.5. HRMS [EI-(+Na)] calcd for $\text{C}_{20}\text{H}_{17}\text{BrN}_2\text{NaO}_4\text{S}$ 482.9985, found 482.9970. The *ee* and *dr* were determined by a chiral phase Chiralpak IC column (60/40 hexane/*i*PrOH, flow rate 0.5 mL/min, λ = 254 nm, t_{major} = 21.7 min, t_{minor} = 27.7 min).



***N*-((*S*)-((*R*)-3-bromo-2-oxoindolin-3-yl)(naphthalen-1-yl)methyl)-4-methylbenzenesulfonamide (8p)**


The title compound was isolated as yellow solid in 81% yield, mp: 130–132 °C, $[\alpha]_{\text{D}}^{25}$ = +99 (c = 1, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 7.96 (d, J = 8.4 Hz, 2H), 7.79 (s, 1H), 7.52 (dd, J = 19.2, 8.0 Hz, 2H), 7.38 (dd, J = 6.7, 5.3 Hz, 2H), 7.31 (dd, J = 9.3, 5.7 Hz, 3H), 7.18 (d, J = 8.2 Hz, 2H), 6.96–6.86 (m, 3H), 6.63 (dd, J = 5.6, 2.7 Hz, 1H), 6.49 (d, J = 8.1 Hz, 2H), 5.90 (d, J = 9.0 Hz, 1H), 1.99 (s, 3H). ^{13}C NMR (75 MHz, CDCl_3) δ 173.6, 142.7, 139.8, 135.6, 133.0, 131.3, 131.1, 130.9, 129.0, 128.5, 128.0, 127.7, 127.2, 127.0, 126.0, 125.5, 125.5, 124.6, 124.1, 123.7, 110.4, 58.5, 57.0, 21.1. HRMS [EI-(+Na)] calcd for $\text{C}_{27}\text{H}_{21}\text{BrN}_2\text{NaO}_3\text{S}$ 544.9566, found 544.9575. The *ee* and *dr* were determined by a chiral phase Chiralpak AD-H column (76/24 hexane/*i*PrOH, flow rate 0.5 mL/min, λ = 220 nm, t_{major} = 30.5 min, t_{minor} = 21.4 min).



***N*-((*S,E*)-1-((*R*)-3-bromo-2-oxoindolin-3-yl)-3-phenylallyl)-4-methylbenzenesulfonamide (8q)**


The title compound was isolated as yellow solid in 89% yield, mp: 120–121 °C, $[\alpha]_{\text{D}}^{25}$ = +85 (c = 1, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 9.01 (s, 1H), 7.73 (d, J = 8.2 Hz, 2H), 7.54 (d, J = 7.5 Hz, 1H), 7.27 (dd, J = 12.9, 4.7 Hz, 4H), 7.17 (d, J = 8.4 Hz, 3H), 7.11 (dd, J = 6.9, 3.7 Hz, 2H), 7.03 (d, J = 7.5 Hz, 1H), 6.86 (d, J = 7.7 Hz, 1H), 6.37 (dd, J = 15.8, 9.3 Hz, 1H), 5.91 (d, J = 15.8 Hz, 1H), 4.50–4.45 (m, 1H), 2.26 (s, 3H). ^{13}C NMR (75 MHz, CDCl_3) δ 175.7, 143.8, 139.9, 136.5, 135.8, 135.4, 130.6, 129.7, 128.5, 128.4, 128.1, 127.6, 126.8, 126.0, 123.6, 122.3, 110.9, 62.2, 57.0, 21.5. HRMS [EI-(+Na)] calcd for

C₂₄H₂₁BrN₂NaO₃S 519.0348, found 519.0349. The *ee* and *dr* were determined by a chiral phase Chiralpak IC column (60/40 hexane/*i*PrOH, flow rate 0.5 mL/min, λ = 254 nm, t_{major} = 18.1 min, t_{minor} = 28.6 min).




***N*-((*S*)-((*R*)-3-bromo-1-methyl-2-oxoindolin-3-yl)(phenyl)methyl)-4-methylbenzenesulfonamide (8r)**

The title compound was isolated as yellow solid in 64%, mp: 61–62 °C, $[\alpha]_{\text{D}}^{25}$ = +33 (*c* = 1, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 7.73 (d, *J* = 7.3 Hz, 1H), 7.51 (d, *J* = 8.2 Hz, 2H), 7.32–7.29 (m, 1H), 7.19 (dd, *J* = 14.2, 7.1 Hz, 1H), 7.00 (dd, *J* = 9.3, 4.5 Hz, 3H), 6.87 (dd, *J* = 13.9, 6.2 Hz, 2H), 6.67 (d, *J* = 7.5 Hz, 2H), 6.57 (d, *J* = 7.7 Hz, 1H), 6.46 (d, *J* = 7.1 Hz, 1H), 4.83 (d, *J* = 7.1 Hz, 1H), 2.81 (s, 3H), 2.28 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 172.1, 143.4, 142.4, 136.2, 133.3, 130.8, 129.3, 128.5, 128.3, 127.5, 127.5, 127.0, 126.8, 123.7, 108.5, 63.9, 58.6, 26.4 (d, *J* = 2.4 Hz), 21.4. HRMS [EI-(+Na)] calcd for C₂₃H₂₁BrN₂NaO₃S 507.0348, found 507.0339. The *ee* and *dr* were determined by a chiral phase phenomenex Lvx 5 μ Cellulose-1 column (90/10 hexane/*i*PrOH, flow rate 0.5 mL/min, λ = 254 nm, t_{major} = 16.5 min, t_{minor} = 25.1 min).




***N*-((*S*)-((*R*)-3-bromo-5-fluoro-2-oxoindolin-3-yl)(4-methoxyphenyl)methyl)-4-methylbenzenesulfonamide (8s)**

The title compound was isolated as yellow solid in 89% yield, mp: 158–159 °C, $[\alpha]_{\text{D}}^{25}$ = +126 (*c* = 1, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 8.40 (s, 1H), 7.49 (d, *J* = 8.2 Hz, 2H), 7.16 (dd, *J* = 7.6, 1.7 Hz, 1H), 7.07 (d, *J* = 8.1 Hz, 2H), 6.96 (td, *J* = 8.8, 2.5 Hz, 1H), 6.78 (d, *J* = 8.7 Hz, 2H), 6.68 (dd, *J* = 8.6, 4.2 Hz, 1H), 6.48 (d, *J* = 8.7 Hz, 2H), 6.42 (d, *J* = 6.3 Hz, 1H), 4.79 (d, *J* = 6.4 Hz, 1H), 3.67 (s, 3H), 2.32 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 174.2, 160.6, 159.7, 157.4, 143.5, 136.4, 135.6 (d, *J* = 2.3 Hz), 130.2, 129.3, 129.0 (d, *J* = 8.5 Hz), 127.4, 125.2, 117.4 (d, *J* = 23.8 Hz), 114.4 (d, *J* = 25.6 Hz), 113.2, 111.5 (d, *J* = 7.9 Hz), 62.8, 58.3, 55.1, 21.5. HRMS [EI-(+Na)] calcd for C₂₃H₂₀BrFN₂NaO₄S 541.0203, found 541.0214. The *ee* and *dr* were determined by a chiral phase Chiralpak IC column (70/30 hexane/*i*PrOH, flow rate 0.5 mL/min, λ = 254 nm, t_{major} = 34.7 min, t_{minor} = 57.3 min).




***N*-((*S*)-((*R*)-3-bromo-5-chloro-2-oxoindolin-3-yl)(4-methoxyphenyl)methyl)-4-methylbenzenesulfonamide (8t)**

The title compound was isolated as yellow solid in 90%, mp: 170–171 °C, $[\alpha]_{\text{D}}^{25}$ = +229 (*c* = 1, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 8.45 (s, 1H), 7.50 (d, *J* = 8.2 Hz, 2H), 7.36 (s, 1H), 7.19 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.09 (d, *J* = 8.1 Hz, 2H), 6.79 (d, *J* = 8.6 Hz, 2H), 6.66 (d, *J* = 8.4 Hz, 1H), 6.49 (d, *J* = 8.7 Hz, 2H), 6.37 (d, *J* = 6.5 Hz, 1H), 4.79 (d, *J* = 6.5 Hz, 1H), 3.67 (s, 3H), 2.33 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 173.9, 159.7, 143.5, 138.2, 136.4, 130.7, 130.2, 129.3, 129.2, 128.7, 127.4, 126.8, 125.3, 113.3, 111.7, 62.8, 58.0, 55.1, 21.5. HRMS [EI-(+Na)] calcd for C₂₃H₂₀BrClN₂NaO₄S 556.9908, found 556.9923. The *ee* and *dr* were determined by a chiral phase Chiralpak IC column (70/30 hexane/*i*PrOH, flow rate 0.5 mL/min, λ = 254 nm, t_{major} = 33.2 min, t_{minor} = 54.5 min).



***N*-((*S*)-((*R*)-3,5-dibromo-2-oxoindolin-3-yl)(4-methoxyphenyl)methyl)-4-methylbenzenesulfonamide (8u)**


The title compound was isolated as yellow solid in 93%, mp: 179–181 °C, $[\alpha]_{\text{D}}^{25} = +189$ ($c = 1$, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 8.50 (s, 1H), 7.52–7.49 (m, 3H), 7.33 (dd, $J = 8.3$, 1.8 Hz, 1H), 7.09 (d, $J = 8.1$ Hz, 2H), 6.79 (d, $J = 8.7$ Hz, 2H), 6.61 (d, $J = 8.3$ Hz, 1H), 6.49 (d, $J = 8.7$ Hz, 2H), 6.40 (d, $J = 6.5$ Hz, 1H), 4.80 (d, $J = 6.6$ Hz, 1H), 3.67 (s, 3H), 2.33 (s, 3H). ^{13}C NMR (75 MHz, CDCl_3) δ 173.9, 159.6, 143.6, 138.7, 136.3, 133.6, 130.2, 129.5, 129.5, 129.4, 127.4, 125.3, 115.8, 113.2, 112.2, 62.8, 58.0, 55.2, 21.5. HRMS [EI(+Na)] calcd for $\text{C}_{23}\text{H}_{20}\text{Br}_2\text{N}_2\text{NaO}_4\text{S}$ 600.9403, found 600.9428. The *ee* and *dr* were determined by a chiral phase Chiralpak IC column (70/30 hexane/*i*PrOH, flow rate 0.5 mL/min, $\lambda = 254$ nm, $t_{\text{major}} = 34.3$ min, $t_{\text{minor}} = 56.4$ min).




***N*-((*S*)-((*R*)-3-bromo-6-chloro-2-oxoindolin-3-yl)(4-methoxyphenyl)methyl)-4-methylbenzenesulfonamide (8v)**

The title compound was isolated as yellow solid in 75%, mp: 104–106 °C, $[\alpha]_{\text{D}}^{25} = +140$ ($c = 1$, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 8.11 (s, 1H), 7.66 (d, $J = 8.1$ Hz, 1H), 7.48 (d, $J = 8.2$ Hz, 2H), 7.17 (dd, $J = 8.2$, 1.6 Hz, 1H), 7.04 (d, $J = 8.2$ Hz, 2H), 6.70 (dd, $J = 8.7$, 5.2 Hz, 3H), 6.61 (d, $J = 7.3$ Hz, 1H), 6.45 (d, $J = 8.7$ Hz, 2H), 4.80 (d, $J = 7.3$ Hz, 1H), 3.66 (s, 3H), 2.31 (s, 3H). ^{13}C NMR (75 MHz, CDCl_3) δ 174.0, 159.5, 143.5, 140.6, 136.6, 130.0, 129.95, 129.3, 128.0, 127.4, 125.8, 125.2, 123.8, 113.2, 111.2, 63.1, 58.0, 55.1, 21.4. HRMS [EI(+Na)] calcd for $\text{C}_{23}\text{H}_{20}\text{BrClN}_2\text{NaO}_4\text{S}$ 556.9908, found 556.9920. The *ee* and *dr* were determined by a chiral phase Chiralpak AD-H column (76/24 hexane/*i*PrOH, flow rate 0.5 mL/min, $\lambda = 220$ nm, $t_{\text{major}} = 30.8$ min, $t_{\text{minor}} = 55.7$ min).

8. Synthesis of aziridine via the product of *anti*-Mannich reaction



The produce of *anti*-Mannich Reaction **8a** (0.2 mmol, 1 equiv.) was dissolved in anhydrous toluene (0.1 mL), subsequently AgNO_3 (0.24 mmol, 1.2 equiv.) and TEA (0.24 mmol, 1.2 equiv.) were added at room temperature. TLC analysis indicated completion of the reaction. The reaction mixture was purified directly by flash chromatography on silica gel. ($\text{AcOEt/PE} = 1 : 5$) to give **9** as a yellow solid.





(2S, 3S)-3-phenyl-1-tosylspiro[aziridine-2,3'-indolin]-2'-one (9)



The product was obtained as a yellow solid in 86% yield, mp: 71–74 °C, $[\alpha]_{\text{D}}^{25} = -27$ (c = 1, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 8.60 (s, 1H), 7.92 (t, *J* = 7.8 Hz, 3H), 7.32 (d, *J* = 8.1 Hz, 2H), 7.23 (s, 5H), 7.12 (t, *J* = 7.6 Hz, 2H), 6.78 (d, *J* = 7.7 Hz, 1H), 4.85 (s, 1H), 2.45 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 169.6, 145.0, 142.0, 136.4, 130.5, 129.9, 129.8, 128.5, 128.2, 127.9, 127.8, 125.4, 122.8, 121.1, 110.8, 55.8 (d, *J* = 2.6 Hz), 53.5, 21.7. HRMS [EI-(+Na)] calcd for C₂₂H₁₈N₂NaO₃S 413.0930, found 413.0922. The *ee* and *dr* were determined by a chiral phase Chiralpak AD-H column (76/24 hexane/*i*PrOH, flow rate 0.5 mL/min, λ = 220 nm, *t*_{major} = 35.2 min, *t*_{minor} = 58.6 min).


9. References



- [1] I. B. Seiple, S. Su, R. A. Rodriguez, R. Gianatassio, Y. Fujiwara, A. L. Sobel, and P. S. Baran. *J. Am. Chem. Soc.* 2010, **132**, 13194.
- [2] V. Benedek, V. Szilard, C. Antal and S. Tibor. *Org. Lett.* 2005, **7**, 1967.
- [3] P. Anbarasan, H. Neumann and M. Beller, *Chem. Eur. J.* 2011, **17**, 4217.
- [4] A. Lee, A. Michrowska, S. S. Mosse, and B. List. *Angew. Chem. Int. Ed.* 2011, **50**, 1707.
- [5] A. Berkessel, B. Seelig, S. Schwengberg, J. Hescheler, and A. Sachinidis, *ChemBioChem*. 2010, **11**, 208.

10. NMR spectra and HPLC for catalysts and *anti*-Mannich reaction products.






































































































	RT (min)	Area (μV*sec)	% Area	Height (μV)	% Height
1	32.899	22881727	46.81	380311	63.78
2	38.321	1625522	3.33	22822	3.83
3	62.700	1702279	3.48	14959	2.51
4	68.638	22670066	46.38	178207	29.89




	RT (min)	Area (μV*sec)	% Area	Height (μV)	% Height
1	32.902	14152791	91.78	235767	92.86
2	38.480	755067	4.90	13283	5.23
3	63.359	59588	0.39	690	0.27
4	68.835	452427	2.93	4151	1.63




	RT (min)	Area ($\mu\text{V}\cdot\text{sec}$)	% Area	Height (μV)	% Height
1	24.401	3993139	5.70	68650	8.21
2	27.948	31162312	44.47	334822	40.03
3	30.729	3884417	5.54	44601	5.33
4	35.642	31028445	44.28	388284	46.43




	RT (min)	Area ($\mu\text{V}\cdot\text{sec}$)	% Area	Height (μV)	% Height
1	24.503	4042584	5.27	78447	7.84
2	28.081	6254806	8.16	77789	7.77
3	31.054	307222	0.40	5517	0.55
4	35.767	66040223	86.16	838932	83.84




	RT (min)	Area ($\mu\text{V}\cdot\text{sec}$)	% Area	Height (μV)	% Height
1	15.628	21229578	47.42	716166	64.47
2	18.611	1133515	2.53	36265	3.26
3	24.928	1135814	2.54	24919	2.24
4	29.474	21268512	47.51	333432	30.02




	RT (min)	Area ($\mu\text{V}\cdot\text{sec}$)	% Area	Height (μV)	% Height
1	15.578	32083514	87.43	1039171	91.29
2	18.582	1311847	3.57	41224	3.62
3	24.964	42897	0.12	1768	0.16
4	29.704	3257474	8.88	56205	4.94




	RT (min)	Area ($\mu\text{V}\cdot\text{sec}$)	% Area	Height (μV)	% Height
1	19.554	3002859	1.87	71441	2.98
2	20.877	74180166	46.19	1602886	66.82
3	27.023	80495464	50.13	680074	28.35
4	31.275	2903997	1.81	44465	1.85




	RT (min)	Area ($\mu\text{V}\cdot\text{sec}$)	% Area	Height (μV)	% Height
1	19.162	335294	0.50	9231	0.62
2	20.982	61974034	91.69	1405527	94.23
3	26.399	3372525	4.99	44105	2.96
4	31.468	1910766	2.83	32700	2.19




	RT (min)	Area ($\mu\text{V}\cdot\text{sec}$)	% Area	Height (μV)	% Height
1	36.149	1329603	6.58	18740	8.79
2	43.453	8499326	42.03	99106	46.49
3	46.539	1436302	7.10	15870	7.44
4	56.972	8956730	44.29	79473	37.28




	RT (min)	Area ($\mu\text{V}\cdot\text{sec}$)	% Area	Height (μV)	% Height
1	36.165	4297851	5.46	63323	9.00
2	43.541	6408536	8.15	79979	11.37
3	46.593	1507620	1.92	19355	2.75
4	56.078	66456653	84.47	540813	76.88




	RT (min)	Area ($\mu\text{V}\cdot\text{sec}$)	% Area	Height (μV)	% Height
1	15.827	11844962	46.61	344740	60.53
2	20.170	862014	3.39	19033	3.34
3	26.105	914678	3.60	20350	3.57
4	28.070	11789077	46.39	185458	32.56




	RT (min)	Area ($\mu\text{V}\cdot\text{sec}$)	% Area	Height (μV)	% Height
1	15.540	104165949	80.16	2627819	83.23
2	20.142	8947106	6.88	221540	7.02
3	26.046	1859627	1.43	51436	1.63
4	28.062	14978029	11.53	256656	8.13




	RT (min)	Area ($\mu\text{V}\cdot\text{sec}$)	% Area	Height (μV)	% Height
1	18.531	45173926	46.56	1113917	59.02
2	20.101	3541881	3.65	75681	4.01
3	30.036	45427711	46.82	661344	35.04
4	33.910	2874591	2.96	36349	1.93




	RT (min)	Area ($\mu\text{V}\cdot\text{sec}$)	% Area	Height (μV)	% Height
1	18.278	118079549	87.29	2538276	88.53
2	20.022	8713490	6.44	187297	6.53
3	30.100	8318646	6.15	137091	4.78
4	33.885	165890	0.12	4554	0.16




	RT (min)	Area (μV*sec)	% Area	Height (μV)	% Height
1	22.969	9500256	49.19	197478	50.44
2	25.942	9811977	50.81	194050	49.56




	RT (min)	Area (μV*sec)	% Area	Height (μV)	% Height
1	22.721	43628899	95.94	867667	94.97
2	26.001	1848444	4.06	46001	5.03




	RT (min)	Area ($\mu\text{V}\cdot\text{sec}$)	% Area	Height (μV)	% Height
1	20.603	17009767	45.56	376794	61.40
2	30.465	1274964	3.42	27489	4.48
3	33.531	1324557	3.55	19073	3.11
4	40.314	17724931	47.48	190330	31.01




	RT (min)	Area ($\mu\text{V}\cdot\text{sec}$)	% Area	Height (μV)	% Height
1	20.410	65572600	80.27	1364838	81.02
2	30.511	13759357	16.84	289176	17.17
3	40.424	2355723	2.88	30593	1.82




	RT (min)	Area ($\mu\text{V}\cdot\text{sec}$)	% Area	Height (μV)	% Height
1	25.549	40692041	48.61	739161	65.33
2	35.392	1222542	1.46	23455	2.07
3	44.894	1322269	1.58	15037	1.33
4	50.707	40471244	48.35	353805	31.27





	RT (min)	Area ($\mu\text{V}\cdot\text{sec}$)	% Area	Height (μV)	% Height
1	25.417	70519207	93.58	1209501	94.34
2	35.389	2347465	3.12	45820	3.57
3	44.950	209029	0.28	2799	0.22
4	50.766	2283370	3.03	23989	1.87




	RT (min)	Area ($\mu\text{V}\cdot\text{sec}$)	% Area	Height (μV)	% Height
1	37.647	10910317	49.30	129386	55.68
2	50.935	11220608	50.70	102980	44.32




	RT (min)	Area ($\mu\text{V}\cdot\text{sec}$)	% Area	Height (μV)	% Height
1	37.392	1842354	2.92	24181	4.55
2	49.928	61287570	97.08	507190	95.45





	RT (min)	Area (μV*sec)	% Area	Height (μV)	% Height
1	19.929	67499456	73.95	1228643	73.82
2	24.632	3516603	3.85	68098	4.09
3	32.979	16970680	18.59	334399	20.09
4	49.519	3295230	3.61	33302	2.00





	RT (min)	Area ($\mu\text{V}\cdot\text{sec}$)	% Area	Height (μV)	% Height
1	20.986	775427	1.58	20706	3.44
2	25.089	23484531	47.88	332918	55.37
3	28.126	24003316	48.93	235827	39.22
4	35.225	789556	1.61	11798	1.96




	RT (min)	Area ($\mu\text{V}\cdot\text{sec}$)	% Area	Height (μV)	% Height
1	21.062	265663	0.19	9044	0.50
2	25.142	131711314	95.65	1737599	95.27
3	28.467	1226798	0.89	18398	1.01
4	35.275	4495210	3.26	58830	3.23




	RT (min)	Area (μV*sec)	% Area	Height (μV)	% Height
1	21.720	39619213	75.95	918309	83.62
2	27.743	1450542	2.78	27018	2.46
3	37.300	10027211	19.22	141348	12.87
4	62.533	1068324	2.05	11492	1.05











	RT (min)	Area ($\mu\text{V}\cdot\text{sec}$)	% Area	Height (μV)	% Height
1	18.011	190838492	40.53	3321998	47.98
2	28.534	234173788	49.74	3173782	45.84
3	42.720	23008748	4.89	253989	3.67
4	62.010	22782637	4.84	173734	2.51




	RT (min)	Area ($\mu\text{V}\cdot\text{sec}$)	% Area	Height (μV)	% Height
1	18.117	126453446	89.03	2958795	92.99
2	28.570	6917905	4.87	120498	3.79
3	42.838	7300599	5.14	87688	2.76
4	62.315	1370020	0.96	14835	0.47












	RT (min)	Area ($\mu\text{V}\cdot\text{sec}$)	% Area	Height (μV)	% Height
1	34.372	7332982	45.97	94598	60.06
2	56.033	7302331	45.78	51761	32.86
3	68.130	658280	4.13	7092	4.50
4	75.133	658721	4.13	4054	2.57



	RT (min)	Area ($\mu\text{V}\cdot\text{sec}$)	% Area	Height (μV)	% Height
1	34.276	59395550	97.02	778465	98.10
2	56.401	1210169	1.98	9361	1.18
3	68.417	280757	0.46	2961	0.37
4	75.494	332869	0.54	2717	0.34



	RT (min)	Area ($\mu\text{V}\cdot\text{sec}$)	% Area	Height (μV)	% Height
1	30.981	31685442	46.73	391074	55.62
2	36.799	2068942	3.05	28231	4.02
3	55.337	32054767	47.28	269358	38.31
4	84.458	1990209	2.94	14429	2.05



	RT (min)	Area ($\mu\text{V}\cdot\text{sec}$)	% Area	Height (μV)	% Height
1	30.841	105748942	94.62	1301154	94.13
2	36.689	5379894	4.81	73364	5.31
3	55.663	636694	0.57	7788	0.56

